- Our Team
- For Patients
- Treatments & Services
- Medical Professionals
Advancing Precision Medicine with Bispecific Antibody Therapy at Maryland Oncology Hematology
“Groundbreaking advancements in medical research have led to the development of bispecific antibody therapy. This new treatment is designed to target and destroy cancer cells with the help of the patient’s immune system. At Maryland Oncology Hematology, we’re proud to offer cutting-edge treatments like bispecific antibody therapy. It provides new hope for patients whose cancer may not respond to standard therapies, giving them access to more personalized and precise care options” says Dr. Najeff Waseem from Maryland Oncology Hematology.
What are Bispecific Antibodies?
Bispecific antibodies work by directing the patient’s T cells to the cancers cells, helping the immune system work more effectively. The antibodies are delivered into the body through an infusion or an injection. Once in the body, the antibody binds to two targets—one side attaches to the cancer cell, and the other connects with the T cell—bringing them together to trigger a more focused immune response.
Who is Eligible for Bispecific Antibody Therapy?
Bispecific antibody therapy is available to patients diagnosed with the following cancers:
- Acute Lymphoblastic Leukemia
- Uveal Melanoma
- Diffuse Large B-Cell Lymphoma
- Follicular Lymphoma
- Multiple Myeloma
- Extensive-Stage Small Cell Lung Cancer
How is Bispecific Antibody Therapy Administered?
Bispecific antibodies are administered in an outpatient infusion center, like Maryland Oncology Hematology.
Healthcare providers use step-up dosing to administer treatment. This gradually increases the amount of medication given during each treatment to minimize side effects. After the initial step-up dosing is completed, bispecific therapy may continue at regular scheduled dosing intervals or as maintenance therapy.
What Are the Benefits of Bispecific Antibody Therapy?
Because bispecific antibodies directly bind immune cells to cancer cells, this treatment is often able to deliver a more accurate immune response in patients with cancer that has been resistant to other treatment options. Studies indicate that bispecific antibodies have shown improvements in outcomes for multiple malignancies.[1]
Maryland Oncology Hematology is proud to provide the latest therapies based on the most recent advancements in cancer research. Our team of experts provides comprehensive support from consultation through treatment and can help determine if bispecific therapy is right for you. Understanding all available options can empower you to make informed decisions about your care.